中医药结合吉非替尼治疗晚期NSCLC的研究现状及思考

Current Situation and Thinking of the Research about the Therapy of Advanced NSCLC by TCM Combined with Gifitinib

近年来随着人们从分子水平对肿瘤发病机制的进一步认识出现了"靶向治疗"的概念。吉非替尼作为一种表皮生长因子受体阻滞剂,在临床上已得到广泛的应用。文章论述了吉非替尼治疗NSCLC的研究进展,探讨了中医药与之结合的研究现状及发展前景。

For the past few years, the conception of ＂targeted therapy＂ appeared along with the further realization in the pathogenesis of tumor from the molecular level. As a kind of Epidermal Growth Factor Receptor, Gefitinib is now widely used in clinic. This article is about the progression of the therapy of NSCLC by Gefinitib, and the current situation and perspective of the research about the combination with TCM.